CVRx (CVRX) AI Stock Analysis

• Market Cap: $196.40M
• Dividend Yield: N/A
• Average Volume (3M): 288.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 23.11%
• EPS Growth: 18.06%
• Country: US
• Employees: 206
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.57
• Shares Outstanding: 26,151,724
• 10 Day Avg. Volume: 342,104
• 30 Day Avg. Volume: 288,986
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 1.99
• Enterprise Value/Gross Profit: 2.37
• Enterprise Value/Ebitda: -2.36
• 1Y Price Target: $10.70
• Price Target Upside: 38.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 49 Neutral
• Price Target: $7.50 ▼(-2.85% Downside)

CVRx's overall stock score is primarily influenced by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. Technical analysis provides mixed signals, while valuation is weak due to negative earnings. The earnings call offers a balanced view with growth prospects and strategic improvements, but increased losses and expenses temper optimism.

Positive Factors

Reimbursement Achievements

Management has successfully moved back into the proper higher-paying APC code two years in a row, indicating a likely appropriate final rate.

Reimbursement and Regulatory

CVRX will benefit from the removal of automatic denials starting next year as its Category I code goes live.

Sales Force Productivity

Much of the future growth is predicated on the sales force productivity ramp with turnover stabilizing.

Sales Performance

Sales came in 2% ahead of the Street, benefiting from some early rewards of sales force stabilization and headcount investments.

Negative Factors

Guidance

The high end of guidance was lowered by one million dollars, which represents only 16 units, and the lowering of the top end of the guidance range seems to cap upside potential.

Sales Force Changes

Q1 miss was attributed to the company being unable to manage the disruption from the deeper-than-expected salesforce changes.

CVRx Business Overview & Revenue Model

Company Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

CVRx generates revenue primarily through the sale of its Barostim System to hospitals and healthcare providers. The company may also engage in partnerships with healthcare institutions and organizations to facilitate the adoption and integration of its technology into clinical practice. Additionally, CVRx may receive revenue from service agreements related to the installation, training, and maintenance of its devices. The company's earnings are influenced by factors such as the adoption rate of its technology, market penetration, and reimbursement policies from insurance providers.

CVRx Financial Statement Overview

Summary

CVRx shows revenue growth and a strong gross profit margin, but faces challenges with negative net income and EBIT margins. The balance sheet is stable with a moderate debt-to-equity ratio, yet negative return on equity reflects financial struggles. Cash flow issues persist with negative operating and free cash flows, indicating potential liquidity concerns.

Income Statement

CVRx has shown consistent revenue growth, with a TTM revenue growth rate of 3.37%. However, the company is currently unprofitable, with negative net profit margins and EBIT margins, indicating challenges in achieving operational efficiency. The gross profit margin remains strong at 84%, suggesting effective cost management at the production level.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.87, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, suggesting a solid capital structure despite the negative profitability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is closely aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.65M	51.29M	39.30M	22.47M	13.04M	6.05M
Gross Profit	45.93M	42.96M	33.04M	17.47M	9.40M	4.61M
EBITDA	-46.15M	-54.89M	-38.73M	-40.74M	-40.60M	-11.48M
Net Income	-52.25M	-59.97M	-41.20M	-41.43M	-43.08M	-14.11M
Balance Sheet
Total Assets	119.56M	133.41M	115.23M	124.94M	152.55M	64.78M
Cash, Cash Equivalents and Short-Term Investments	95.03M	105.93M	90.57M	106.19M	142.07M	59.11M
Total Debt	50.54M	50.43M	30.61M	7.09M	0.00	19.28M
Total Liabilities	61.63M	62.36M	39.28M	15.76M	6.59M	358.01M
Stockholders Equity	57.93M	71.06M	75.95M	109.18M	145.96M	-293.24M
Cash Flow
Free Cash Flow	-39.43M	-40.51M	-39.61M	-43.36M	-28.91M	-16.41M
Operating Cash Flow	-39.12M	-39.14M	-39.02M	-42.68M	-27.73M	-16.10M
Investing Cash Flow	-306.00K	-1.36M	-591.00K	-685.00K	-1.18M	-311.00K
Financing Cash Flow	64.04M	55.87M	23.98M	7.49M	111.88M	49.78M

CVRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Positive. The current price of 7.72 is below the 20-day moving average (MA) of 7.83, above the 50-day MA of 6.98, and below the 200-day MA of 10.76, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 68.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVRX.

CVRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	73 Outperform	$232.99M	58.63	7.41%	―	26.86%	―
MASS	56 Neutral	$233.47M	―	-46.85%	―	14.65%	-86.36%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
CVRX	49 Neutral	$196.40M	―	-92.33%	―	23.11%	18.06%
LNSR	49 Neutral	$154.20M	―	-350.22%	―	29.34%	-283.53%
MYO	47 Neutral	$40.83M	―	-68.32%	―	93.07%	13.25%
TLSI	46 Neutral	$138.61M	―	271.41%	―	45.50%	53.07%

CVRx Corporate Events

CVRx Appoints Brent Binkowski as New COO

On August 4, 2025, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, effective August 11, 2025. Binkowski brings over 20 years of experience in medical devices, which is expected to enhance CVRx’s operations. The company reported a 15% increase in total revenue for the second quarter of 2025, reaching $13.6 million, driven by growth in the U.S. heart failure market. The number of active implanting centers in the U.S. grew by 27% since June 2024. CVRx is also benefiting from favorable CMS proposals for Barostim reimbursement, positioning the company for continued growth.

The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.

CVRx Confirms Directors and Accounting Firm at Meeting

On June 3, 2025, CVRx, Inc. held its annual meeting of stockholders where key decisions were made. The election of two Class I directors, Kevin Ballinger and Mitch Hill, was confirmed, and the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are pivotal for CVRx’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (CVRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.